ArticleBMC neurology2025
Anti-NMDAR antibodies are not prevalent in Lyme neuroborreliosis: a retrospective cohort study.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Infection-Triggered Immune Dysregulation and Immunopathology in Lyme Disease: Mechanisms and Clinical Implications.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFour published case reports have proposed Lyme neuroborreliosis (LNB) as a trigger for anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. In this study, we examined the prevalence of anti-NMDAR antibodies in a well-characterized cohort of patients with LNB.
methodsIn this retrospective cohort study, archived cerebrospinal fluid (CSF) samples from patients diagnosed with LNB between 2001 and 2012 were analyzed for anti-NMDAR IgG using a standard commercial cell-based assay. LNB diagnosis followed the European Federation of Neurological Societies guidelines. To identify potential later development of anti-NMDAR encephalitis, an infectious disease specialist systematically reviewed medical records in 2021, and the national reference center for neural autoantibody testing verified testing history in 2025.
resultsWe included 82 patients with a median age of 52 years (interquartile range [IQR]: 34-63); 55% were male. Median symptom duration before diagnosis was 21 days (IQR: 7-45). The most frequent symptoms were cranial nerve palsy (51%) and radiating pain (50%). Among 70 patients with available CSF data, limited by access to laboratory records, the median CSF leukocyte count was 124 × 10
conclusionAnti-NMDAR antibodies were not detected in the CSF of LNB patients, suggesting their presence is rare in this population at diagnosis. Although the sample size may limit statistical power, the absence of later clinical suspicion or testing supports the hypothesis that LNB is an uncommon trigger for anti-NMDAR encephalitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.